Data Requests
Current Data Requests
There are no current data requests at this time.
Archived Data Requests
340B Report Data Request posted March 11, 2026
Under 2024 Md. Laws, Chap. 962 (HB 1056) - PDF, the Maryland Prescription Drug Affordability Board (PDAB) may require covered entities and 340B manufacturers to report information as necessary to complete a study on the implementation, impact, and finances of the 340B program in Maryland.
PDAB analyzes the data and present findings in the 340B report; analysis will include but not be limited to aggregate totals, ranges, averages, and trends. This data collection is only authorized for the purpose of this 340B study and associated report.
- Who's Eligible to Respond: Covered Entities and 340B Manufacturers
- Initial Due Date: April 10, 2026
- Extension Due Date: June 15, 2026
We are posting a Data Request for the following information for the 340B study.
Covered entities are required to respond to the Data Request. Manufacturers are eligible but not required to respond to the Data Request. Certain entities have received a direct Data Request by e-mail from the Board. An entity that has not received a Data Request from the Board may submit relevant information in accordance with 2024 Md. Laws, Chap. 962 (HB 1056).
Submitters should use the Excel template to support the submission of data for the Data Request. For questions or assistance, please contact [email protected].
Designating Material as Confidential, Trade-Secret or Proprietary
If your entity would like to designate certain data elements as confidential, trade-secret, or proprietary, please email a document containing the following information to PDAB at [email protected].
- Identification of data elements that are to be treated as confidential, trade-secret, or proprietary
- Designate by referring to the excel template (column number, column title, cell number, etc.)
- Certification that data elements listed in (1) have been treated by your entity as confidential, trade-secret, or proprietary
- Certification that data elements listed in (1) are not publicly available
- Explanation of steps taken on behalf of your entity to protect the data elements listed in (1) from disclosure
For any questions regarding submission of confidential, trade-secret, or proprietary information, and for all other questions, please contact [email protected].